To access this element change to forms mode OFF
Grant Award View - GA205201
Targeting metastatic triple-negative breast cancer with a selective...
GA ID:
GA205201
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
3-Nov-2021
Publish Date:
13-Dec-2021
Category:
Medical Research
Grant Term:
1-Jan-2022 to 1-Jan-2025
Value (AUD):
$674,218.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Ideas Grants
Grant Activity:
Targeting metastatic triple-negative breast cancer with a selective oncogenic JNK inhibitor
Purpose:
While JNK is a potent oncogene in TNBC, there are no effective JNK-targeting therapies due to the fact that this signalling pathway regulates numerous cellular functions. Leveraging a recent screen of 114,000 compounds, we have identified a novel molecule, called K12, that specifically inhibits the tumour promoting activity of JNK. Now, we will further the preclinical evaluation of K12, to generate a world-first drug capable of preventing metastatic outgrowth in TNBC
GO ID:
GO Title:
2021 Ideas Grants
InternalReferenceId:
2021/GNT2011728
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Sydney
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, NSW
Postcode:
Multiple
Country:
AUSTRALIA